North Star Asset Management Inc. Makes New Investment in Novo Nordisk A/S $NVO

North Star Asset Management Inc. purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,676 shares of the company’s stock, valued at approximately $1,950,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $25,000. Scarborough Advisors LLC bought a new position in Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Transamerica Financial Advisors LLC increased its stake in Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after purchasing an additional 403 shares during the period. Johnson Financial Group Inc. increased its stake in Novo Nordisk A/S by 128.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after purchasing an additional 384 shares during the period. Finally, Kingdom Financial Group LLC. bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $41,000. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on NVO shares. BMO Capital Markets reissued a “market perform” rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Thursday. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $46.27 on Friday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The stock has a market capitalization of $206.58 billion, a P/E ratio of 11.31, a P/E/G ratio of 4.25 and a beta of 0.76. The company’s 50-day moving average is $47.98 and its 200 day moving average is $43.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.43 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a $0.5786 dividend. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is presently 20.05%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s National Medical Products Administration accepted Novo Nordisk’s application for an oral version of Wegovy. The filing is not an approval, but authorization could expand access to Novo’s obesity treatment and strengthen its position against Eli Lilly in China. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Neutral Sentiment: Novo’s shares recently moved above their 200-day moving average, a potentially constructive technical signal. However, the stock remains well below its prior peak, and the longer-term trend is still being shaped primarily by earnings and competitive developments. Novo Nordisk stock price passes above 200 day moving average
• Negative Sentiment: Deutsche Bank downgraded NVO to Sell from Hold and reduced its price target to 265 Danish kroner from 290 kroner. The bank cited doubts about Novo’s ability to resume growth following mixed second-quarter results, increasing competition and concerns about an impending patent-related revenue cliff, particularly around 2027. Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell
• Negative Sentiment: Analysts also questioned Novo’s development pipeline after Ziltivekimab was described as effectively out of the picture following a failed late-stage cardiovascular trial. This removes a potential future growth driver as investors look for products that can offset slowing momentum in Ozempic and Wegovy. Novo’s 2027 growth rebound faces fresh doubts
• Negative Sentiment: Investors continue to monitor intensifying competition from Eli Lilly and lower-cost or counterfeit versions of Novo’s blockbuster GLP-1 medicines. These pressures could affect pricing, market share and the pace of revenue growth. Novo Nordisk shares drop as bank downgrade reflects growth concerns

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.